Top

Reactions Weekly

Published in:

01-07-2023 | Acne Inversa | Case report

Adalimumab/betamethasone-dipropionate/calcipotriol

Lack of efficacy and paradoxical hidradenitis suppurativa: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Martora F, et al. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'. Clinical and Experimental Dermatology 48: 701-703, No. 6, et al. Jun 2023. Available from: URL: http://doi.org/10.1093/ced/llad082

Title: Adalimumab/betamethasone-dipropionate/calcipotriol
Lack of efficacy and paradoxical hidradenitis suppurativa: case report
Publication date: 01-07-2023
Publisher: Springer International Publishing
Keywords: Acne Inversa
Adalimumab
Vulgar Psoriasis
Guselkumab
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-42990-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adalimumab/betamethasone-dipropionate/calcipotriol

Lack of efficacy and paradoxical hidradenitis suppurativa: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Multiple drugs

Budesonide/formoterol/pembrolizumab

Antineoplastics

Cladribine

Rivaroxaban

Immunosuppressants